Are there any alternatives for transfusion of AB plasma as universal donor in an emergency release setting?

Balvers, Kirsten; Saleh, Sarah; Klinkspoor, J. H.; Goslings, J. C.; Juffermans, Nicole P.

doi:10.1111/trf.13527

Cited by 5 publications

(4 citation statements)

References 23 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus it appears safe to utilize group A plasma as the first option for trauma patients of unknown ABO group, a finding consistent with, and confirmatory of, those of recent smaller studies . The safety of transfusing plasma that is ABO compatible but not identical (such as group A plasma to a group O recipient) has been questioned but could not be answered in this study as group O recipients were excluded from analysis . Only five of our study subjects were younger than 15 years of age; therefore, we consider our conclusion to apply only to adult trauma patients (defined by American College of Surgeons as ≥15 years).…”

Section: Discussionsupporting

confidence: 82%

Safety of the use of group A plasma in trauma: the STAT study

2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Safety of the use of group A plasma in trauma: the STAT study

2017

View full text Add to dashboard Cite

show abstract

“…AB FDP is considered a universal donor; therefore, it is best suited for use at the point of injury. However, the low prevalence of AB blood donors limits the product's availability even more 12,13 …”

Section: Discussionmentioning

confidence: 99%

“…However, the low prevalence of AB blood donors limits the product's availability even more. 12,13 An analysis of one bottle of lyophilized plasma tested 30 years after manufacture revealed that most of the biochemical constituents appeared to be within the normal ranges. Much of the enzymatic activity was preserved.…”

Section: Discussionmentioning

confidence: 99%

Post‐expiry stability of freeze‐dried plasma under field conditions – Can shelf life be extended?

et al. 2021

View full text Add to dashboard Cite

Background This prospective study evaluated the effect of routine, uncontrolled, Israeli field storage conditions on the safety and efficacy of Lyo‐Plas N Freeze‐Dried Plasma (FDP) at the end of the manufacturer's shelf life, and up to 24 months post expiry. Clotting factors V, VIII and XI, proteins S, C, fibrinogen, PTT, ATIII, VWF, and INR as well as TEG, DDM, residual moisture, pH, and sterility of FDP returned from field units after uncontrolled storage were evaluated. Study Design and Methods Parameters measured at the end of manufacturer shelf life, as well as 6, 12, 18, and 24 months after expiry, were compared to those of freshly supplied FDP doses. Results Changes were found when comparing freshly supplied FDP to all field‐stored groups in INR, PT, PTT, pH, fibrinogen, and factor VIII. A significant change was also seen in Factor XI in the 12, 18, and 24 months post‐expiry samples, Factor V and R in the 24 months post‐expiry samples, MA in the 12, 24 months post‐expiry group, and Protein C in the 18 months post‐expiry group. An increase in the residual moisture from 0.90% in freshly supplied FDP to 1.35% in 24 months post‐expiry FDP.; all p < .05. No growth was found in sterility analysis. Conclusion Despite uncontrolled field storage conditions, the findings demonstrate that the safety and efficacy of FDP units, stored in uncontrolled conditions are only slightly affected, even beyond their expiration date. This information allows consideration of possibly extending the shelf life.

show abstract

“…Although this approach can be effective in the COVID-19 patients [10], it has some limitations including the dearth of eligible recovered patients and ABO-incompatibility. Except for individuals with AB blood group (universal plasma donors) [11], others have cold reactive natural antibodies directed against red blood cells (RBCs), high concentration (≥1:64) of which leads to various complications and symptoms [12]. Despite the mentioned practical advantage of the AB group, low prevalence limits its widespread application for CP therapy; the frequency of blood groups is race/ethnicity-dependent, but overall, their prevalence in white populations is as follows: O > A>B > AB (45 %, 40 %, 11 %, and 4%, respectively) [13].…”

Section: Introductionmentioning

confidence: 99%

Ubiquitous convalescent plasma: An artificial universal plasma for COVID-19 patients

Bardsiri

Kouhbananinejad

Vahidi

et al. 2021

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Objectives and background: In December 2019, the first case of COVID-19 was reported in Wuhan, China. Its causative virus, is a novel strain of RNA viruses with high mortality rate. There is no definitive treatment, but among available approaches the use of recovered patients' plasma containing specific antibodies can enhance the immune response against coronavirus. However, the dearth of eligible donors and also ABO incompatibility in plasma transfusion, have limited this therapeutic method. Therefore, it is highly desirable to introduce a simple procedure that allows efficient reduction or even removal of natural ABO antibodies. Accordingly, we aimed to evaluate a RBC-mediated adsorption technique that reduces the titer of the mentioned antibodies in plasma. Methods/materials: This experimental study was conducted in Kerman University of Medical Sciences, Kerman, Iran. The pre-and post-incubation antibody titers of 168 plasma samples were determined. For incubation, each plasma sample was exposed (60 min) to different percentages of RBCs at room temperature or 4 • C. Results: The results evidenced that both the concentration of RBCs and temperature had significant decreasing effects on antibody titer (P < 0.001) and all concentrations significantly reduced titer. Compared to RT, 4 • C further reduced the antibody titer. Overall, the best incubation condition for reducing antibody titer in all blood groups was 4 • C and 2% RBCs concentration. Conclusion:The presented adsorption procedure is able to produce universal plasma (we call it Ubiquitous Convalescent Plasma) with a non-immunogenic level of ABO mismatch antibodies which can be used for COVID-19 patients with any type of blood group with desirable simplicity, feasibility, and efficacy.

show abstract

Are there any alternatives for transfusion of AB plasma as universal donor in an emergency release setting?

Abstract: Studies are insufficient to formulate advice about alternatives for transfusion of AB plasma as universal donor plasma in the emergency setting due to the small number of studies. The results of this review underline the need for further research.

Cited by 5 publications

References 23 publications

Safety of the use of group A plasma in trauma: the STAT study

Safety of the use of group A plasma in trauma: the STAT study

Post‐expiry stability of freeze‐dried plasma under field conditions – Can shelf life be extended?

Ubiquitous convalescent plasma: An artificial universal plasma for COVID-19 patients

Contact Info

Product

Resources

About